Mr. Marc-Andre Massue reports

DIAGNOS ANNOUNCES VOTING RESULTS OF ANNUAL MEETING OF SHAREHOLDERS

Diagnos Inc. has released the voting results of its annual general and special meeting of shareholders held earlier today.

Election of directors

Vincent Duhamel, Andre Larente, Dr. Reid Maclellan, Francis Bellido and Robert Dunn were elected as directors of the corporation to hold office until the closing of the next annual meeting of the shareholders.

Appointment of auditor

Raymond Chabot Grant Thornton LLP was reappointed as auditor of the corporation for the ensuing year.

Amendment to the stock option plan

The disinterested shareholders of the corporation approved a special resolution pursuant to which the maximum number of common shares of the corporation that may be issued under the stock option plan be set at 10.2 million, representing an increase of 1.2 million common shares.

The amendment to the corporation's stock option plan remains subject to TSX Venture Exchange acceptance.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation with a mission of early detection of critical health issues through the use of CARA (computer-assisted retina analysis). CARA is a teleophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA's image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the Internet and is compatible with all recognized image formats and brands of fundus cameras and is EMR (electronic medical record) compatible. CARA is a cost-effective tool for screening large numbers of patients in real time. CARA complies with local regulations, is FDA (Food and Drug Administration) cleared for commercialization in the United States, is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.

We seek Safe Harbor.